MGX — Metagenomi Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2024-02-09.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-05 | Irish Jian See Remarks | Open-market sale | 3.7K | 1.30 | 4.9K |
| 2026-06-05 | Wapnick Pamela Chief Financial Officer | Open-market sale | 2.9K | 1.30 | 3.7K |
| 2026-06-05 | Wein Matthew See Remarks | Open-market sale | 558 | 1.30 | 725 |
| 2026-04-01 | Irish Jian See Remarks | Grant or award | 46.0K | 0.00 | 0 |
| 2026-04-01 | Wapnick Pamela Chief Financial Officer | Grant or award | 24.0K | 0.00 | 0 |
| 2026-04-01 | Wein Matthew See Remarks | Grant or award | 11.0K | 0.00 | 0 |
| 2026-03-05 | Irish Jian Chief Executive Officer | Open-market sale | 1.6K | 1.60 | 2.6K |
| 2026-03-05 | Wapnick Pamela Chief Financial Officer | Open-market sale | 1.6K | 1.60 | 2.5K |
| 2026-03-05 | Wein Matthew See Remarks | Open-market sale | 482 | 1.60 | 771 |
| 2025-12-05 | Thomas Brian C. Director | Open-market sale | 3.8K | 1.77 | 6.8K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1.4M | 1.1M |
| RENAISSANCE TECHNOLOGIES LLC | 1.1M | 787.9K |
| Catalio Capital Management, LP | 708.9K | 529.0K |
| Peapod Lane Capital LLC | 682.9K | 516.8K |
| TWO SIGMA INVESTMENTS, LP | 665.7K | 496.8K |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 530.4K | 395.8K |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 512.1K | 382.2K |
| GEODE CAPITAL MANAGEMENT, LLC | 480.2K | 358.2K |
| PURA VIDA INVESTMENTS, LLC | 354.3K | 264.4K |
| BlackRock, Inc. | 308.4K | 230.1K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Metagenomi Therapeutics, Inc. (MGX) filed form 8-K · 2026-08-10 · SEC EDGAR
Ask the AI about MGX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →